WO1998017107A1 - Peptides a activite insecticide isoles a partir du venin de l'araignee phidippus - Google Patents
Peptides a activite insecticide isoles a partir du venin de l'araignee phidippus Download PDFInfo
- Publication number
- WO1998017107A1 WO1998017107A1 PCT/US1996/016875 US9616875W WO9817107A1 WO 1998017107 A1 WO1998017107 A1 WO 1998017107A1 US 9616875 W US9616875 W US 9616875W WO 9817107 A1 WO9817107 A1 WO 9817107A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- phidippus
- sequence
- spider venom
- insecticidally effective
- Prior art date
Links
- 239000002708 spider venom Substances 0.000 title claims description 33
- 241001657619 Phidippus Species 0.000 title claims description 25
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract description 30
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract description 16
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 147
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 109
- 238000000034 method Methods 0.000 claims abstract description 59
- 241000607479 Yersinia pestis Species 0.000 claims abstract description 27
- 230000000749 insecticidal effect Effects 0.000 claims abstract description 26
- 239000013604 expression vector Substances 0.000 claims abstract description 25
- 241000923163 Phidippus audax Species 0.000 claims abstract description 21
- 239000000203 mixture Substances 0.000 claims abstract description 16
- 238000003259 recombinant expression Methods 0.000 claims abstract description 12
- 241000238631 Hexapoda Species 0.000 claims description 36
- 241000701447 unidentified baculovirus Species 0.000 claims description 32
- 239000013598 vector Substances 0.000 claims description 25
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 23
- 230000014509 gene expression Effects 0.000 claims description 21
- 238000004519 manufacturing process Methods 0.000 claims description 13
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims description 10
- 108091026890 Coding region Proteins 0.000 claims description 8
- 208000033952 Paralysis flaccid Diseases 0.000 claims description 5
- 208000028331 flaccid paralysis Diseases 0.000 claims description 5
- 238000004113 cell culture Methods 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 241000255777 Lepidoptera Species 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 241000500891 Insecta Species 0.000 claims 4
- 230000017074 necrotic cell death Effects 0.000 claims 1
- 239000002435 venom Substances 0.000 abstract description 48
- 231100000611 venom Toxicity 0.000 abstract description 48
- 210000001048 venom Anatomy 0.000 abstract description 48
- 235000018102 proteins Nutrition 0.000 description 85
- 108020004414 DNA Proteins 0.000 description 39
- 108700012359 toxins Proteins 0.000 description 35
- 210000004027 cell Anatomy 0.000 description 33
- 150000001413 amino acids Chemical class 0.000 description 32
- 239000003053 toxin Substances 0.000 description 29
- 231100000765 toxin Toxicity 0.000 description 29
- 229940024606 amino acid Drugs 0.000 description 26
- 235000001014 amino acid Nutrition 0.000 description 26
- 239000000872 buffer Substances 0.000 description 22
- 241000256244 Heliothis virescens Species 0.000 description 20
- 239000012465 retentate Substances 0.000 description 19
- 108020004635 Complementary DNA Proteins 0.000 description 17
- 238000010804 cDNA synthesis Methods 0.000 description 17
- 241000239290 Araneae Species 0.000 description 16
- 238000005571 anion exchange chromatography Methods 0.000 description 16
- 239000002299 complementary DNA Substances 0.000 description 16
- 230000001769 paralizing effect Effects 0.000 description 15
- 206010033799 Paralysis Diseases 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 238000003752 polymerase chain reaction Methods 0.000 description 13
- 108091034117 Oligonucleotide Proteins 0.000 description 12
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 239000000523 sample Substances 0.000 description 11
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 10
- 239000002953 phosphate buffered saline Substances 0.000 description 10
- 238000011098 chromatofocusing Methods 0.000 description 9
- 230000007935 neutral effect Effects 0.000 description 9
- 238000000926 separation method Methods 0.000 description 9
- 108020004705 Codon Proteins 0.000 description 8
- 101710182846 Polyhedrin Proteins 0.000 description 8
- 241000700605 Viruses Species 0.000 description 8
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 230000000813 microbial effect Effects 0.000 description 8
- 241000196324 Embryophyta Species 0.000 description 7
- 241000256247 Spodoptera exigua Species 0.000 description 7
- 230000003321 amplification Effects 0.000 description 7
- 238000010367 cloning Methods 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 238000003199 nucleic acid amplification method Methods 0.000 description 7
- 241000201370 Autographa californica nucleopolyhedrovirus Species 0.000 description 6
- 108010076504 Protein Sorting Signals Proteins 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 241000255993 Trichoplusia ni Species 0.000 description 6
- 125000000539 amino acid group Chemical group 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000004587 chromatography analysis Methods 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 239000002917 insecticide Substances 0.000 description 6
- 238000003780 insertion Methods 0.000 description 6
- 230000037431 insertion Effects 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 229910021645 metal ion Inorganic materials 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 229920001184 polypeptide Polymers 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- 102000003922 Calcium Channels Human genes 0.000 description 5
- 108090000312 Calcium Channels Proteins 0.000 description 5
- 238000001042 affinity chromatography Methods 0.000 description 5
- 238000005194 fractionation Methods 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- 241001367049 Autographa Species 0.000 description 4
- 102100034343 Integrase Human genes 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- KSPIYJQBLVDRRI-UHFFFAOYSA-N N-methylisoleucine Chemical compound CCC(C)C(NC)C(O)=O KSPIYJQBLVDRRI-UHFFFAOYSA-N 0.000 description 4
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 4
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 4
- 108700005078 Synthetic Genes Proteins 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 238000011109 contamination Methods 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- -1 insecticides Chemical class 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 239000000575 pesticide Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 229910000162 sodium phosphate Inorganic materials 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 241000238898 Agelenopsis aperta Species 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 238000001712 DNA sequencing Methods 0.000 description 3
- 102000018899 Glutamate Receptors Human genes 0.000 description 3
- 108010027915 Glutamate Receptors Proteins 0.000 description 3
- 101710138657 Neurotoxin Proteins 0.000 description 3
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 239000013522 chelant Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- XVOYSCVBGLVSOL-UHFFFAOYSA-N cysteic acid Chemical compound OC(=O)C(N)CS(O)(=O)=O XVOYSCVBGLVSOL-UHFFFAOYSA-N 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 239000002581 neurotoxin Substances 0.000 description 3
- 231100000618 neurotoxin Toxicity 0.000 description 3
- 239000002751 oligonucleotide probe Substances 0.000 description 3
- 230000001323 posttranslational effect Effects 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 239000001226 triphosphate Substances 0.000 description 3
- 235000011178 triphosphate Nutrition 0.000 description 3
- 238000000108 ultra-filtration Methods 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- MRTPISKDZDHEQI-YFKPBYRVSA-N (2s)-2-(tert-butylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC(C)(C)C MRTPISKDZDHEQI-YFKPBYRVSA-N 0.000 description 2
- NPDBDJFLKKQMCM-SCSAIBSYSA-N (2s)-2-amino-3,3-dimethylbutanoic acid Chemical compound CC(C)(C)[C@H](N)C(O)=O NPDBDJFLKKQMCM-SCSAIBSYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- 108010017826 DNA Polymerase I Proteins 0.000 description 2
- 102000004594 DNA Polymerase I Human genes 0.000 description 2
- 239000003298 DNA probe Substances 0.000 description 2
- 241000017055 Dipluridae Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical group O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 2
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 2
- QEFRNWWLZKMPFJ-ZXPFJRLXSA-N L-methionine (R)-S-oxide Chemical compound C[S@@](=O)CC[C@H]([NH3+])C([O-])=O QEFRNWWLZKMPFJ-ZXPFJRLXSA-N 0.000 description 2
- QEFRNWWLZKMPFJ-UHFFFAOYSA-N L-methionine sulphoxide Natural products CS(=O)CCC(N)C(O)=O QEFRNWWLZKMPFJ-UHFFFAOYSA-N 0.000 description 2
- 241001465803 Orgyia pseudotsugata Species 0.000 description 2
- 241000356457 Salticidae Species 0.000 description 2
- 241000239226 Scorpiones Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108020005202 Viral DNA Proteins 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 241000385736 bacterium B Species 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 2
- 230000005859 cell recognition Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 210000000087 hemolymph Anatomy 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 230000001151 other effect Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- 239000002795 scorpion venom Substances 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 2
- LINMATFDVHBYOS-MBJXGIAVSA-N (2s,3r,4s,5r,6r)-2-[(5-bromo-1h-indol-3-yl)oxy]-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C=C12 LINMATFDVHBYOS-MBJXGIAVSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- NCQMBSJGJMYKCK-ZLUOBGJFSA-N Ala-Ser-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O NCQMBSJGJMYKCK-ZLUOBGJFSA-N 0.000 description 1
- 241000024188 Andala Species 0.000 description 1
- JHFNSBBHKSZXKB-VKHMYHEASA-N Asp-Gly Chemical compound OC(=O)C[C@H](N)C(=O)NCC(O)=O JHFNSBBHKSZXKB-VKHMYHEASA-N 0.000 description 1
- 241001203868 Autographa californica Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000193388 Bacillus thuringiensis Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 241000254173 Coleoptera Species 0.000 description 1
- 241000256113 Culicidae Species 0.000 description 1
- 206010011703 Cyanosis Diseases 0.000 description 1
- 241001635274 Cydia pomonella Species 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 241000408655 Dispar Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 241000255967 Helicoverpa zea Species 0.000 description 1
- 241000238900 Hololena curta Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 101710203526 Integrase Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- 241000239271 Leiurus quinquestriatus hebraeus Species 0.000 description 1
- 241000920471 Lucilia caesar Species 0.000 description 1
- 241000721703 Lymantria dispar Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 240000004658 Medicago sativa Species 0.000 description 1
- 235000017587 Medicago sativa ssp. sativa Nutrition 0.000 description 1
- 241001481690 Mesobuthus eupeus Species 0.000 description 1
- 241000714177 Murine leukemia virus Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010028347 Muscle twitching Diseases 0.000 description 1
- 240000001307 Myosotis scorpioides Species 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- 241000407918 Neodiprion sertifer Species 0.000 description 1
- 241001221062 Nephila clavata Species 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 101100342977 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) leu-1 gene Proteins 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 108700020497 Nucleopolyhedrovirus polyhedrin Proteins 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- 241000256251 Spodoptera frugiperda Species 0.000 description 1
- VCXWRWYFJLXITF-AUTRQRHGSA-N Tyr-Ala-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 VCXWRWYFJLXITF-AUTRQRHGSA-N 0.000 description 1
- SYOMXKPPFZRELL-ONGXEEELSA-N Val-Gly-Lys Chemical compound CC(C)[C@@H](C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)O)N SYOMXKPPFZRELL-ONGXEEELSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 238000003277 amino acid sequence analysis Methods 0.000 description 1
- 238000012197 amplification kit Methods 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 108010047857 aspartylglycine Proteins 0.000 description 1
- 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910000366 copper(II) sulfate Inorganic materials 0.000 description 1
- 244000038559 crop plants Species 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 239000005549 deoxyribonucleoside Substances 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000003673 groundwater Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000000383 hazardous chemical Substances 0.000 description 1
- 231100000206 health hazard Toxicity 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 238000012872 hydroxylapatite chromatography Methods 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000002919 insect venom Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000029226 lipidation Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000001471 micro-filtration Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000036403 neuro physiology Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000000361 pesticidal effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000006069 physical mixture Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 108091006082 receptor inhibitors Proteins 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- 241000701366 unidentified nuclear polyhedrosis viruses Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
- A01N37/44—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing at least one carboxylic group or a thio analogue, or a derivative thereof, and a nitrogen atom attached to the same carbon skeleton by a single or double bond, this nitrogen atom not being a member of a derivative or of a thio analogue of a carboxylic group, e.g. amino-carboxylic acids
- A01N37/46—N-acyl derivatives
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
- A01N63/50—Isolated enzymes; Isolated proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
- C07K14/43518—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from spiders
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
Definitions
- This invention relates to insecticidally effective proteins. More particularly, the invention relates, inter alia, to a family of insecticidally effective proteins which may be isolated from Phidippus spider venom as well as methods for controlling invertebrate pests.
- the most widely used microbial pesticides are derived from the bacterium Bacillus Thuringiensis (hereinafter B.t). This bacterial agent is used to control a variety of pests, including leaf-eating caterpillars, beetles and mosquitos.
- B.t Bacillus Thuringiensis
- U.S. Patent No. 4,797,279 issued January 10, 1989 to Karamata, et al. discloses hybrid bacterial cells comprising the gene coding for B.t. kurstaki delta-endotoxin and the gene coding for B.t. tenebrionis delta- endotoxin and their preparation.
- the B.t. hybrids are active against pests susceptible to B.t. kurstaki strains as well as against pests susceptible to B.t.
- these hybrids have useful insecticidal properties which are superior to those observed by physical mixtures of the parent strains in terms of level of insecticidal activity, or in terms of spectrum of activity, or both.
- the insecticidal compositions comprising such microorganisms may be used to combat insects by applying the hybrids in an insecticidally effective amount to the insects or to their environment.
- Another derivation from the bacterium B.t. was disclosed in European Patent Application, Publication No. 0325400A1 , issued to Gilroy and Wilcox.
- This invention relates to a hybrid toxin gene which is toxic to lepidopteran insects.
- the invention comprises a hybrid delta endotoxin gene comprising part of the B.t. var. kurstaki HD-73 toxin gene and part of the toxin gene from B.t. var. kurstaki strain HD-1.
- the hybrid toxin gene (DNA) encoding a protein having activity against lepidopteran insects was disclosed.
- the bacterium B.t. was also utilized for its insecticidal properties in
- This invention concerns hybrid pesticidal toxins which are produced by the fusion of an insect gut epithelial cell recognition region of a B.t. gene to diphtheria toxin B chain to prepare a hybrid B.t. toxin which is active against lepidopteran insects. It was suggested that the hybrid B.t. gene may be inserted into a plant or cloned into a baculovirus to produce a toxin which can be recovered. Alternatively, the host containing the hybrid B.t. gene can be used as an insecticide by direct application to the environment of the targeted insect.
- scorpion venom was identified as a possible source of compounds providing insecticidal properties.
- Two insect selective toxins isolated from the venom of the scorpion Leirus quinquestriatus quinquestriatus were revealed in Zlotkin, et al., Arch Biochem and Biophysis, 1985, 240, 877-87.
- Zlotkin, et al., Arch Biochem and Biophysis, 1985, 240, 877-87 In a study related to their chemical and pharmacological properties, it was revealed that one toxin induced fast excitatory contractive paralysis of fly larvae and the other induced slow depressant flaccid paralysis. Both affected sodium conductance in neurons.
- This method may be easier than the electroporation of protoplasts because the ultimate goal is to pollinate the flowers and "let the flowers do the work" rather than to regenerate the plant.
- the process consists of collecting pollen, germinating it in a germinating medium for 30-60 minutes after which the pollen tube will start to come out of the pollen grain, adding the desired DNA to the liquid suspension containing the pollen, administering an electric shock to open the pores of the pollen, washing the excess DNA away, and putting the altered pollen under'the stigma of a plant and waiting until seeds are formed. This may be an easy method to move any gene into crop plants.
- the protein-producing microbial cell itself is used as the delivery system so no purification of the produced compound is necessary.
- Any protein, polypeptide, amino acid, or compound, including insecticides, that may be produced by microbial means may be the starting material of the invention.
- U.S. Patent No. 4,879,236 issued November 7, 1989 to Smith and Summers relates to a method for incorporating a selected gene coupled with a baculovirus promoter into a baculovirus genome to produce a recombinant baculovirus expression vector capable of expression of the selected gene in an insect cell.
- the method involves cleaving baculovirus DNA to produce a DNA fragment comprising a polyhedrin gene or portion thereof, including a polyhedrin promoter.
- To prepare a recombinant transfer vector the DNA fragment is inserted into a cloning vehicle and then a selected gene is inserted into this modified cloning vehicle such that it is under the control of the polyhedrin promoter.
- the recombinant transfer vector is then contacted in insect cells with a baculovirus DNA so as to effect recombination and incorporation of the selected gene into the baculovirus genome.
- the baculovirus Autographa califomica (AcMNPV) and its associated polyhedrin promoter were found to be useful in producing a viral expression vector capable of extremely high levels of expression of a selected gene in an insect host cell.
- the inventors suggest that the expression vector might be used in a system for controlling insects by selecting a gene which produces a protein which is toxic to a specific insect or to a spectrum of insects and cloning that gene into the AcMNPV expression vector. They suggest that the vector could be applied to the plant or animal to be protected. The recombinant virus could invade the cells of the intestinal wall following ingestion by the insect and begin replication. The possibility of using DNA technology to incorporate a synthetic gene which encodes a neurotoxin found in scorpion venom was explored in Carbonell, et al., Gene, 1988, 73, 409-18.
- This article describes the possibility of using DNA technology to incorporate a synthetic gene which encodes a neurotoxin found in the venom of the scorpion, Buthus eupeus, into the baculovirus genome to improve baculovirus pesticides.
- Three methods of expression using the polyhedrin promoter-based AcMNPV expression system to effect toxin production were studied. Expression of the 36 codon gene alone provided minuscule production of the toxin. Some success was found with the attachment of a signal peptide to the toxin. Significant levels of protein were produced when the toxin gene was fused to the N-terminus of polyhedrin. However, production was ten to twenty-fold less than that observed for polyhedrin itself.
- WO 89/07608 issued August 24, 1989 to Cherksey, et al., discloses that these active low molecular weight factors reversibly bind to calcium channels with sufficient specificity and affinity to extinguish calcium conductance in neurons and to permit isolation and purification of calcium channel structures. These venoms were found to be toxic to mammals.
- spider toxins were discussed in Jackson and Parks, Ann. Rev. Neurosci, 1989, 12, 405-14. This article describes the great heterogeneity in the toxins of different taxa. It recognizes that experiments have suggested species-specific properties of calcium channels and the spider venoms might provide calcium channel antagonists. The spider venoms discussed are found to affect vertebrates. The article also identifies spider venoms as possible sources of insect-specific toxins for agricultural applications.
- U.S. Patent No. 4,918,107 issued April 17, 1990 to Nakajima, et al. relates to a compound which has glutamate receptor inhibitor activity, a process for preparing the same, and an insecticidal composition containing the same. Accordingly, due to a combination of problems associated with conventional chemical insecticides, including pest resistance and injurious effects on non-target organisms, there exists a continuing need for the development of novel means of invertebrate pest control.
- novel insecticidally effective proteins derived from, for example, a spider of the genus Phidippus. Two proteins, exhibiting insecticidal activity, were isolated from the chromatographical separation of Phidippus whole venom toxin. The proteins are designated BW2 and BW5. Further provided by this invention are methods for controlling invertebrate pests with insecticidal compositions containing insecticidal proteins or the genes encoding these proteins and insecticidal compositions.
- novel recombinant expression vectors and genetically engineered insecticidal microbes and methods of controlling invertebrate pests comprising contacting said pests with a recombinant baculovirus capable of expressing an effective amount of an insecticidally effective peptide substantially isolatable from Phidippus spider venom and agriculturally or horticulturally acceptable salts thereof.
- Figure 1 depicts a chromatogram representing the separation of the C- 100 retentate of Phidippus audax whole venom by immobilized metal ion chromatography (I MAC) on a TSK Chelate 5 PW column loaded with Cu”.
- I MAC immobilized metal ion chromatography
- Figure 2 depicts a chromatogram representing the separation of fraction 2 (from Figure 1) by anion exchange chromatography on a Mono-Q column.
- Figure 3 depicts a chromatogram representing the separation of fraction 5 (from Figure 1) by anion exchange chromatography on a Mono-Q column.
- Figures 4A and 4B depict chromatograms representing the separation of fractions 2 (Figure 4B) and 5 (Figure 4B) (obtained from Figures 2 and 3, respectively) by chromatofocusing on a Mono-P column.
- Phidippus audax is a member of the Family Salticidae, better known as the jumping spiders. It is widely distributed in the United States, and is especially common in the southern states. P. audax is one of the larger members of the family, sometimes exceeding half an inch in length. P. audax, like most other salticids, is a hunting spider, relying on agility and visual acuity to detect and capture prey.
- the mechanism of action of the insecticidally effective proteins of this invention is unknown. It has been found that these toxins produce a characteristic set of symptoms in lepidopteran larvae. These include a rapidly developing flaccid paralysis, complete cessation of dorsal vessel contractions (heartbeats), and in some cases a gradually spreading zone of necrotic or cyanotic discoloration. Paralysis generally develops in less than ten minutes, and was observed in some cases to develop in less than two minutes. These effects are identical to those caused by whole Phidippus venom, strongly implying that the toxic proteins described in this invention are primarily responsible for the insecticidal effects of this venom.
- Phidippus venom One source of insecticidally effective proteins is Phidippus venom. Spider venom can be removed from Phidippus by any method known such as venom gland extraction from cephalothorax. However, in order to avoid impurities within the spider venom and the isolated toxins, the spider venom preferably is obtained by electrical stimulation of the spiders to cause release of the venom and subsequent suction to collect the released venom and prevent contamination of the venom by regurgitate or hemolymph as described in U.S. Patent No. 4,925,664.
- the spider venom Once the spider venom is obtained by electrical milking techniques, it can be fractionated into its protein (toxin) components by high performance liquid chromatography (HPLC) with a variety of separation modes such as ion exchange and immobilized metal ion affinity chromatography (IMAC), and chromatofucusing.
- HPLC high performance liquid chromatography
- IMAC immobilized metal ion affinity chromatography
- chromatofucusing ion exchange and immobilized metal ion affinity chromatography
- the toxins thus isolated can be assayed for insecticidal activity and the DNA and amino acid sequences determined by methods known to those in the art.
- Insecticidally effective proteins This invention, in one of its aspects, provides a family of insecticidally effective proteins, and insecticidally effective fragments thereof and agriculturally or horticulturally acceptable salts thereof.
- amino acid sequence determination can be performed in any way known to those in the art such as
- N-terminal amino acid sequencing and use of an automated amino acid sequencer The entire amino acid sequence can be determined.
- insecticidally effective proteins are expected to be within the scope of the invention. That is, it is believed other insecticidally effective proteins in the family exist and may be isolatable from Phidippus as well as other sources in addition to the two detailed herein.
- a substantially isolated DNA sequence encoding a protein of this invention may be determined by methods known to those in the art.
- the genes responsible for the production of proteins from a source can be isolated and identified. Numerous methods are available to obtain the gene responsible for the production of a protein. Examples include Fuqua, et al., Biotechnique, Vol. 9, No. 2 (Aug 1990); Frohman, "RACE: Rapid amplification of cDNA ends", in PCR protocols, Innis, et al. (Eds.), Academic Press, San Diego, CA, (1990) and U.S. Patent No. 4,703,008, which patent is incorporated herein by reference.
- DNA oligonucleotides are synthesized which encode the determined amino acid sequence or which represents the complementary DNA (cDNA) strand to such a DNA molecule which encodes the determined amino acid sequence.
- These synthetic DNA oligonucleotides may then be used to probe for DNA sequence homology in cell clones containing recombinant DNA molecules comprising, in part, DNA sequences derived from the genomic DNA of an organism such as a spider or derived from cDNA copies of mRNA molecules isolated from cells or tissues of an organism such as a spider.
- DNA molecules of fifteen (15) nucleotides or more are required for unique identification of an homologous DNA, said number requiring unique determination of at least five (5) amino acids in sequence.
- each amino acid may be encoded by up to six (6) unique trinucleotide DNA sequences or codons. Therefore, it is impractical to test all possible synthetic DNA probes individually, and pools of several such DNA oligonucleotides are used concomitantly as probes. The production of such pools which are referred to as "degenerate" probes is well known in the art.
- PCR Polymerase Chain Reaction
- Primers or oligonucleotide probes, are designed which correspond to the 5' ends of both complimentary strands of the sequence of interest.
- PCR with the addition of deoxynucleotide bases and a heat stable polymerase, the portion of the DNA sequence between the primers is then synthetically constructed. Numerous cycles of PCR thus allow a logarithmic amplification of even a single copy of a DNA sequence.
- RNA is isolated from the spider and purified by methods known in the art. Reverse transcriptase and random primers are then used to reverse transcribe the spider RNA into cDNA. Alternatively, oligo(dT) can be used, instead of random primers, to specifically reverse transcribe mRNA.
- the "degenerate" mixture of synthetic DNA oligonucleotides encoding the 5'-termini of the cDNA, corresponding to the amino-terminus of the protein, and the 5'-termini of its complimentary strand, corresponding to the carboxy-terminus of the protein, is then designed with a restriction endonuclease site on their 5'-termini. This restriction site allows for the insertion of the cloned DNA fragment into a cloning vector.
- This DNA oligonucleotide mixture is used to prime a PCR reaction. Because the synthetic DNA oligonucleotide mixture used to prime the PCR reaction is specific to the desired sequence, only the desired cDNA will be effectively amplified.
- the resultant product represents an amplified cDNA which can be ligated to any of a number of known cloning vectors.
- "families" of proteins or peptides may exist in spider venoms which will have similar amino acid sequences and that in such cases, the use of mixed oligonucleotide primer sequences may result in the amplification of one or more of the related cDNAs encoding these related proteins.
- Genes encoding related proteins are also within the scope of the invention as the related proteins also have useful insecticidal activities.
- the produced cDNA sequence can be cloned into an appropriate vector using conventional techniques, analyzed and the nucleotide base sequence determined.
- a direct amino acid translation of these PCR products will reveal that they corresponded to the complete coding sequence for the mature protein.
- the portion of the DNA sequence which might encode amino acids corresponding to precursor and or propeptide regions may not be obtained by this approach.
- Such sequences may be determined by isolation of genomic or cDNA clones using the cDNA clone produced in this approach as a hybridization probe which is within the scope of the art.
- insecticidally effective proteins of this invention are believed to be useful in controlling invertebrate pests such as those in the order Lepidoptera.
- Methods for using the insecticidally effective proteins of this invention may include contacting the pests with an effective amount of a protein of this invention.
- Methods of contacting an invertebrate pest with a protein to control said pests are known. Examples include the insertion of a gene encoding a toxic peptide or protein into the genome of a baculovirus, such as the Autographa califomica nuclear polyhedrosis virus. Of course, methods of controlling invertebrate pests using the proteins of this invention can be used in combination with other methods of controlling pests.
- expression vector includes vectors which are capable of expressing the desired peptide or protein from DNA sequences contained therein, where such sequences are operably linked to other sequences capable of effecting their expression, /. e., promoter sequences. It is implied, although not always explicitly stated, that these expression vectors must be replicable in the host organisms either as episomes or as an integral part of the chromosomal DNA. Clearly a lack of replicability would render them effectively inoperable. In sum, "expression vector” is given a functional definition, and any DNA sequence which is capable of supporting expression of a specified DNA code disposed therein is included in this term as it is applied to the specified sequence.
- expression vectors of utility in recombinant DNA techniques are often in the form of "plasmids" which refer to circular double stranded DNA which, in their vector form are not bound to the chromosome.
- Plasmid and “vector” are used interchangeably as the plasmid is the most commonly used form of vector.
- Recombinant host cells refers to cells which have been transformed with vectors constructed using recombinant DNA techniques.
- a recombinant expression vector comprising a DNA sequence which encodes an insecticidally effective peptide substantially isolatable from Phidippus spider venom.
- the vector is capable of effecting the expression of the coding sequence in transformed cells.
- recombinant host cells with a DNA sequence encoding an insecticidally effective peptide substantially isolatable from Phidippus spider venom in a manner allowing the host cell to express the peptide.
- Such recombinant expression vectors may be employed in methods for producing insecticidally effective peptides. Such methods comprise culturing recombinant host cells wherein a recombinant expression vector transformed, transfected or otherwise applied in said host cells has a DNA sequence encoding the peptide and recovering the insecticidally effective peptide from the recombinant host cell culture or host organism. In such methods the vector is capable of supporting with host cell factors the expression of the coding sequence in the transformed cells.
- Provision of a suitable DNA sequence encoding the desired protein permits the production of the protein using recombinant techniques now known in the art.
- the coding sequence can be obtained by retrieving a cDNA or genomic sequence from a native source of the protein or can be prepared synthetically using the accurate amino acid sequence determined from the nucleotide sequence of the gene.
- advantage can be taken of known codon preferences of the intended host.
- control sequences such as promoters, and preferably enhancers and termination controls, are readily available and known in the art for a variety of hosts. See e.g., Sambrook, et al., Molecular Cloning a Laboratory Manual, Second Ed., Cold Spring Harbor Press, New York (1989).
- the desired proteins can be prepared in both procaryotic and eucaryotic systems, resulting, in the case of many proteins, in a spectrum of processed forms.
- the most commonly used procaryotic system remains E. coli, although other systems such as B. subtilis and Pseudomonas are also expected to be useful.
- Suitable control sequences for procaryotic systems include both constitutive and inducible promoters including the lac promoter, the trp promoter, hybrid promoters such as tac promoter, the lambda phage PI promoter.
- foreign proteins may be produced in these hosts either as fusion or mature proteins.
- the sequence produced may be preceded by a methionine which is not necessarily efficiently removed.
- the peptides and proteins claimed herein may be preceded by an N-terminal Met when produced in bacteria.
- constructs may be made wherein the coding sequence for the peptide is preceded by an operable signal peptide which results in the secretion of the protein. When produced in procaryotic hosts in this matter, the signal sequence is removed upon secretion.
- eucaryotic hosts are also now available for production of recombinant foreign proteins.
- eucaryotic hosts may be transformed with expression systems which produce the desired protein directly, but more commonly signal sequences are provided to effect the secretion of the protein.
- Eucaryotic systems have the additional advantage that they are able to splice introns which may occur in the messenger RNA encoding proteins of higher organisms.
- Eucaryotic systems also provide a variety of post-translational mechanisms which result in, for example, glycosylation, oxidation or derivatization of certain amino acid residues, conformational control, and so forth.
- eucaryotic systems include yeast, insect cells, mammalian cells, avian cells, and cells of higher plants.
- Suitable promoters are available which are compatible and operable for use in each of these host types as well as are termination sequences and enhancers, as e.g. the baculovirus polyhedrin promoter.
- promoters can be either constitutive or inducible.
- the MTH promoter can be induced by the addition of heavy metal ions.
- the DNA encoding it is suitably ligated into the expression system of choice, and the system is then transformed into the compatible host which is then cultured and maintained under conditions wherein expression of the foreign gene takes place.
- the insecticidally effective protein of this invention thus produced is recovered from the culture, either by lysing the cells or from the culture medium as appropriate and known to those in the art.
- a “deletion” is defined as a polypeptide in which one or more internal amino acid residues are absent.
- An “addition” is defined as a polypeptide which has one or more additional internal amino acid residues as compared to the wild type.
- a “substitution” results from the replacement of one or more amino acid residues by other residues.
- a protein "fragment” is a polypeptide consisting of a primary amino acid sequence which is identical to a portion of the primary sequence of the protein to which the polypeptide is related.
- substitutions are those which are conservative, /. e., wherein a residue is replaced by another of the same general type.
- naturally-occurring amino acids can be subclassified as acidic, basic, neutral and polar, or neutral and nonpolar and/or aromatic. It is generally preferred that encoded peptides differing from the native form contain substituted codons for amino acids which are from the same group as that of the amino acid replaced.
- the basic amino acids Lys, Arg, and His are interchangeable; the acidic amino acids Asp and Glu are interchangeable; the neutral polar amino acids Ser, Thr, Cys, Gin, and Asn are interchangeable; the nonpolar aliphatic acids Gly, Ala, Val, lie, and Leu are conservative with respect to each other (but because of size, Gly and Ala are more closely related and Val, lie and Leu are more closely related), and the aromatic amino acids Phe, Tip, and Tyr are interchangeable. While Pro is a nonpolar neutral amino acid, it represents difficulties because of its effects on conformation, and substitutions by or for Pro are not preferred, except when the same or similar conformational results can be obtained.
- Polar amino acids which represent conservative changes include Ser, Thr, Gin, Asn; and to a lesser extent, Met.
- Ala, Gly, and Ser seem to be interchangeable, and Cys additionally fits into this group, or may be classified with the polar neutral amino acids. Some substitutions by codons for amino acids from different classes may also be useful. Because recombinant materials for the proteins of the invention are provided, these proteins can be made by recombinant techniques as well as by automated amino acid synthesizers. Because of the variety of post- translational characteristics conferred by various host cells, various modifications for the naturally-occurring proteins will also be obtained.
- a "modified" protein differs from the unmodified protein as a result of post- translational events which change the glycosylation, amidation or lipidation pattern, or the primary, secondary, or tertiary structure of the protein and are of course included within the scope of the invention as claimed.
- amino acids which are not encoded by the gene may also be made.
- Alternative residues include, for example, the w amino acids of the formula H 2 N(CH 2 ) n COOH wherein n is 2-6. These are neutral, nonpolar amino acids, as are sarcosine (Sar), t-butylalanine (t-BuAla), t- butylglycine (t-BuGly), N-methyl isoleucine (N-Melle), and norleucine (Nleu).
- Phenylglycine for example, can be substituted for Trp, Tyr or Phe an aromatic neutral amino acid; citrulline (Cit) and methionine sulfoxide (MSO) are polar but neutral, cyclohexyl alanine (Cha) is neutral and nonpolar, cysteic acid (Cya) is acidic, and ornithine (Orn) is basic.
- the conformation conferring properties of the praline residues may be obtained if one or more of these is substituted by hydroxyproline (Hyp).
- insecticidally effective peptide alone or in combination with another insect toxin is expected to be useful in potentiating or enhancing the toxicity of microbes such as baculoviruses and hybrid bacteria.
- baculoviruses including those that infect Heliothis virescens (cotton bollworm), Orgyia pseudotsugata (Douglas fir tussock moth), Lymantia dispar (gypsy moth), Autographa califomica (alfalfa looper), Neodiprion sertifer (European pine fly), and Lanspcyresia pomonella (codling moth) have been registered in some countries and used as pesticides. Introduction of at least one insect-selective toxin into the genome is expected to significantly enhance the potency of such pesticides.
- a recombinant expression vector expected to be particularly suitable for use in this invention is a baculovirus expression vector such as the type disclosed in U.S. Patent 4,879,236, which patent is incorporated by reference as if fully set forth herein.
- Other publications describing a method for recombinant protein expression using baculovirus vectors include Tomalski, et al., Nature, 1991 , 352, 82-85; Stewart, et al., Nature, 1991 , 352, 85-88; and McCutchen, et al., Biotechnology, 1991 , 9, 848-851.
- the vector is expected to be useful in a system where a DNA sequence encoding an insecticidally effective peptide substantially isolatable from Phidippus spider venom can be cloned into baculovirus such as Autographa califomica (AcMNPV) expression vector as described in U.S. 4,879,236 and Miller, et al., Science, 1983, 219, 715-721.
- AcMNPV Autographa califomica
- the recombinant expression vector virus could then be applied to the plant or animal upon which the insect is a pest, and when the virus is ingested by the pest insect, the recombinant virus will invade the cells of the intestinal wall and begin replication.
- the gene for the insecticidally effective protein will be expressed, resulting in the disablement or death of the insect in a shorter period than if the insect had ingested the wild type AcMNPV virus.
- a hybrid virus also expected to be useful is taught in European Patent Application 0340948.
- the hybrid virus expressing the DNA of this invention is expected to yield a virus having an altered insect host range.
- fusion proteins could be expressed as a single polypeptide product of a hybrid gene consisting of DNA of this invention and a specific insect gut cell recognition protein to direct the expressed insecticidally effective peptide to the host insect target.
- prokaryotic and eucaryotic microbes can be transformed to express a hybrid toxin gene encoding an insecticidally effective protein by the method taught in European Patent Application 0325400.
- Hybrid bacterial cells comprising a plasmid with the gene coding for the protein of this invention are expected to be useful in the method of this invention. Insects would be controlled by applying the hybrids to insects. See e.g., U.S. Patent 4,797,279 which patent is incorporated by reference as if fully set forth herein.
- An insecticidal composition comprising an insecticidally effective amount of a protein according to this invention and agriculturally or horticulturally acceptable salts thereof in an agriculturally or horticulturally acceptable carrier therefor is also provided.
- the spider venom is preferably obtained by electrical stimulation of the spiders to cause release of the venom and subsequent suction to collect the released venom and prevent contamination of the venom by regurgitate or hemolymph as described in U.S. Patent No. 4,925,664.
- Crude venom (stored at -80°C) was thawed and mixed thoroughly with the starting solvent prior to chromatography.
- the venom was fractionated by high performance liquid chromatography (HPLC) incorporating Beckman System Gold 126 solvent delivery and 168 photodiode array detector modules. Several columns and conditions were used in the purifications described below.
- HPLC column fractions were generally concentrated in CENTRICON 0 C-10 or C-3 microconcentrators for assay in TBW larvae as follows. Column fractions were placed in C-3 filters and centrifuged at approximately 4000 x g for 70 min (this concentrated the samples to approximately 200 ml).
- Immobilized metal ion affinity chromatography was performed on a Progel 6 TSK Chelate 5PW column (7.5 x 75 mm, from Supelco) freshly loaded with Cu 2 ions (40 mM CuS0 4 (aq)).
- the A buffer was 20 mM NaH 2 P0 4 , 1 mM imidazole, 0.5 M NaCI adjusted to pH 7.0 with 10 M NaOH.
- the B buffer was 20 mM NaH 2 P0 4 , 20 mM imidazole, 0.5 M NaCI adjusted to pH 7.0 with 10 M NaOH.
- the column was equilibrated in the A buffer and eluted at 1 ml/min with a 40 min linear gradient from 0% B to 100% B after 5 min at 0% B. After 5 min at 100% B the column was returned to 0% B over 2 min and equilibrated with A buffer before the next injection was made.
- the effluent was monitored at 280 nm and fractions collected with a Gilson model 203 fraction collector.
- Anion exchange chromatography was performed on a Mono-Q column (5.0 x 50 mm).
- the A buffer was 25 mM Tris base adjusted to pH 7.5 with 6 N HCI and the B buffer was 25 mM Tris base, 1.0 M NaCI adjusted to pH 7.5 with 6 N HCI.
- the column was eluted at a flow rate of 1 ml/min with a linear gradient (begun 5 minutes after injection) from 0 to 100% B buffer over 75 min.
- the column was taken to 50% B buffer over 2 min, held at 50% B buffer for 4 min, returned to 0% B buffer over 2 min and equilibrated before the next injection.
- Chromatography was monitored at 280 nm and fractions collected with a Gilson model 203 fraction collector.
- Protein concentrations were determined using the Pierce BCA assay reagents and methods unless otherwise noted. N-terminal amino acid sequence analysis was performed at the Biotechnology Center at Utah State University in Logan, Utah.
- insects tested were last instar, laboratory reared larvae of the tobacco budworm (TBW), Heliothis virescens, the cabbage looper (CL), Trichoplusia ni, and the beet armyworm (BAW), Spodoptera exigua. All samples, whether whole venom or venom fractions, were prepared in filter- sterilized physiological saline (PBS), pH 6.5. Samples were administered by injection into the hemocoel at or near the lateral midline of the fourth abdominal segment; the needle was inserted at a shallow angle to avoid injury to internal organs. After treatment the larvae were held in individual Petri dishes with food and observed periodically for paralysis and other effects such as feeding inhibition.
- PBS physiological saline
- WVE whole venom equivalents
- venom was diluted 1 :10 or 1 :100 in sterile-filtered phosphate- buffered saline (PBS), pH 6.5. Three microliter aliquots of these venom solutions (providing doses of 0.3 or 0.03 WVE/larva) were injected into TBW, BAW, and CL larvae as described previously. The larvae were analyzed initially and after 24 hours for paralysis and the results are indicated in Table I. As indicated in Table I, whole venom contained paralytic activity for all three species tested. Control larvae, which were injected with PBS alone, were unaffected.
- PBS sterile-filtered phosphate- buffered saline
- Phidippus audax Whole Venom Contains Paralytic Activity Species Dose (WVE/larva ⁇ 24 hours a 48 hours 1
- This value represents the number of larvae paralyzed versus total number of larvae injected.
- This value represents the dosage of the fraction injected in terms of mg of protein per g of larvae.
- This value represents the number of larvae paralyzed versus total number of larvae injected.
- Example 3 Fractionation of C-100 Retentate of Phidippus audax Whole Venom by Immobilized Metal Ion Affinity Chromatography and Identification of Paralytic Fractions.
- the C-100 retentate of whole venom was separated by IMAC using a
- TSK Chelate 5 PW column (7.5 mm x 75 mm) loaded with Cu +2 .
- the column was eluted at 1 ml/min with a 40 min linear gradient from 0% B to 100% B after 5 min at 0% B.
- Buffer A was 20 mM NaH 2 P0 4 , 0.5 M NaCI, 1 mM imidazole adjusted to pH 7.0.
- Buffer B was 20 mM NaH 2 P0 4 , 0.5 M NaCI, 20 mM imidazole adjusted to pH 7.0.
- the column was monitored at 280 nm and fractions collected with a Gilson model 203 fraction collector. This separation, depicted in the chromatogram shown in Figure 1 , resulted in the collection of eight fractions.
- This value represents the number of larvae paralyzed versus total number of larvae injected.
- Example 4 Fractionation of C-100 Retentate of Phidippus audax Whole Venom by Immobilized Metal Ion Affinity Chromatography followeded by Anion Exchange Chromatography and Identification of Paralytic Fractions.
- IMAC preparation of C-100 retentate of whole venom using a Mono-Q column (5.0 x 50 mm).
- the A buffer was 25 mM Tris base adjusted to pH 7.5 and the B buffer was 25 mM Tris base, 1.0 M NaCI adjusted to pH 7.5.
- the column was eluted at a flow rate of 1 ml/min with a linear gradient from 0 to 100% B buffer over 75 min after 5 min at 0% B. This chromatography was monitored at 280 nm and fractions collected with a Gilson model 203 fraction collector.
- This value represents the number of larvae paralyzed versus total number of larvae injected.
- Example 5 Fractionation of C-100 Retentate of Phidippus audax Whole Venom by Immobilized Metal Ion Affinity Chromatography followeded by Anion Exchange Chromatography followeded by Chromatofocusing and Identification of Paralytic Fractions.
- IMAC fraction 5 was injected into TBW larvae as described previously. The larvae were analyzed initially and after 24 and 48 hours for paralysis and feeding inhibition and the results are indicated in Table V. As indicated in
- the chromatofocusing product of AEC fraction 2 of IMAC fraction 2 is referred to as BW2.
- the chromatofocusing product of AEC 2 of IMAC fraction 5 is referred to as BW5.
- the N-terminal sequence of both proteins is: Asp-Gly-lle-Val-Gly-Lys-Ala-Ser-Ser-Tyr-Ala-Ala-
- This value represents the dosage of the fraction injected in terms of mg of protein per g of larvae.
- This value represents the number of larvae paralyzed versus total number of larvae injected.
- Example 6 Isolating the coding genes for insecticidally effective peptides isolated from Phidippus audax venom
- RNA is extracted from the cephalothoraxes using the protocol of Chomczynski, et al., Analytical Biochemistry, 1987, 162, 156. Polyadenylated messenger RNA (mRNA) is purified using oligo d(T) cellulose
- Messenger RNA is reverse transcribed to cDNA with murine leukemia virus reverse transcriptase (Bethesda Research Laboratories, MD) using the manufacturer's protocol.
- the 20 ml reaction mixture contains the enzyme buffer as supplied in a cDNA synthesis kit (Boehringer Mannheim, IN), 50 ng of mRNA, 2 units of RNase H, 30 ng of d(T)Not I primer (Promega, Madison,
- reaction mixture Wl
- 1 mM each deoxynucleoside triphosphates 1 mM
- 100 mg of reverse transcriptase 1 mM
- the reaction mixture is incubated for 1 h at 37° C and continued for 10 minutes at 42° C.
- the reaction mixture is ethanol precipitated and resuspended in 20 ml water.
- a degenerate primer DNA sequence mixture which could code for amino acid residues 1 through 8 is designed using codon preferences to reduce degeneracy.
- DNA polymerase was initially described by Saikki, et al., Science, 1988, 239, 487.
- 5 ml of the Phidippus cephalothorax cDNA is used as template in a polymerase chain reaction containing reagents contained in the GENEAMP 6 DNA amplification kit (Perkin Elmer Cetus, CA).
- the amplification reaction contains the sense and antisense primers in a 2 mM concentration, 100 mM of each deoxynucleotide triphosphate, and 4 units of the thermostable recombinant Taql polymerase.
- the reaction is run in a DNA
- Step #5 Cloning of PCR Products
- PCR products from both high and low stringency reactions are purified to remove unincorporated primers using a Centricon-100 (Amicon) molecular size separation unit.
- the retained products are then digested with the restriction enzyme Not I (MBR), Milwaukee, Wl), which cleaves within the downstream (3' end) primer leaving a sticky end.
- the vector, pKS (Stratagene, LaJolla, CA)
- EcoRV US Biochemical
- Not I to generate sites specific for directional cloning.
- Vector and insert are ligated and transformed into complex DH5aF'. Colony lifts are screened with the ⁇ P labeled internal probe and candidate colonies are further characterized by sequencing (US BiochemicaPs Sequenase Version 2.0) mini- prep DNA using the internal probe as primer.
- a lepidopteran signal sequence (Jones, et al., J. Biol. Chem., 1990, 265, 8596), is constructed from two synthetic oligonucleotides using the method of Rossi, et al., J. Biol. Chem., 1982, 257, 9226. Two 48mers are purified by ion exchange chromatography. These two oligonucleotides share eleven base pairs of complementary sequence at their 3' termini. When the sequences are annealed in the presence of the four deoxy-ribonucleoside triphosphates and the Klenow fragment of DNA polymerase I, a double- stranded product is synthesized.
- Reaction products are purified using hydroxylapatite chromatography and the double-stranded DNA molecules are digested with Aatll, the restriction enzymes appropriate for inserting this sequence upstream of cDNA cloned into pKS-DK9c. Subclones are screened for the insertion of the signal sequence and evaluated by DNA sequencing.
- DNA sequencing confirms an in-frame fusion between the two cDNA sequences.
- the entire synthetic gene construct is excised and adapted for cloning into the Nhel site of pBlueBac, a baculovirus transfer vector (Vialard, et al., J. Virology, 1990, 64, 3-50). Subclones are sequenced to confirm the correct insertion of the construct.
- DNA sequencing of plasmid WR9 confirms the insertion of the synthesized gene in the baculovirus transfer vector pBlueBac.
- the use of the pBlueBac vector expedites the screening process as insertion of the recombinant gene into the baculovirus genome is accompanied by co-expression of b-galactosidase and detectable by a color change when grown on indicating media.
- Recombinant baculoviruses are produced by transfection of Spodoptera frugiperda strain Sf9 (ATCC# CRL1711) cells with a mixture of 1 mg AcMNPV viral DNA and 2 mg plasmid DNA using the protocol of Summers and Smith (in "A Manual of Methods for Baculovirus Vectors and Insect Cell Culture Procedures", Texas Agricultural Experiment Bulletin No. 1555, 1988).
- Four days post-transfection dilutions of the cell supernatant are plaqued on 100 mm plates seeded with 5 x 10 6 Sf9 cells and covered with agarose containing Bluo-gal (Gibco BRL, Gaithersburg, MD) as substrate.
- recombinants are detectable by their pale blue color. Plaques are picked using a pasteur pipet and eluted in 1 ml of media. This eiuent is used to re-infect Sf9 cells seeded into a T-25 flask. Three days post-infection a small volume of supernatant is collected from six different isolates and used to prepare viral DNA. PCR amplification using viral specific primers from the region surrounding the polyhedrin gene confirms that viral isolates contain an appropriately sized insert and lacked any wild-type contamination. Titered stocks of the recombinant viruses are then prepared for in vivo and in vitro testing.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Agronomy & Crop Science (AREA)
- Wood Science & Technology (AREA)
- Pest Control & Pesticides (AREA)
- Plant Pathology (AREA)
- Environmental Sciences (AREA)
- Dentistry (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Insects & Arthropods (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US1996/016875 WO1998017107A1 (fr) | 1996-10-21 | 1996-10-21 | Peptides a activite insecticide isoles a partir du venin de l'araignee phidippus |
AU75183/96A AU7518396A (en) | 1996-10-21 | 1996-10-21 | Insecticidally effective peptides isolatable from (phidippus) spider venom |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US1996/016875 WO1998017107A1 (fr) | 1996-10-21 | 1996-10-21 | Peptides a activite insecticide isoles a partir du venin de l'araignee phidippus |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998017107A1 true WO1998017107A1 (fr) | 1998-04-30 |
Family
ID=22255999
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1996/016875 WO1998017107A1 (fr) | 1996-10-21 | 1996-10-21 | Peptides a activite insecticide isoles a partir du venin de l'araignee phidippus |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU7518396A (fr) |
WO (1) | WO1998017107A1 (fr) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5441934A (en) * | 1992-01-24 | 1995-08-15 | Fmc Corporation | Insecticidally effective peptides |
US5457178A (en) * | 1993-07-07 | 1995-10-10 | Fmc Corporation | Insecticidally effective spider toxin |
-
1996
- 1996-10-21 WO PCT/US1996/016875 patent/WO1998017107A1/fr active Application Filing
- 1996-10-21 AU AU75183/96A patent/AU7518396A/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5441934A (en) * | 1992-01-24 | 1995-08-15 | Fmc Corporation | Insecticidally effective peptides |
US5457178A (en) * | 1993-07-07 | 1995-10-10 | Fmc Corporation | Insecticidally effective spider toxin |
Non-Patent Citations (1)
Title |
---|
JOURNAL ECONOMIC ENTOMOLOGY, February 1992, Vol. 85, No. 1, QUISTAD et al., "Insecticidal Activity of Spider (Araneae), Centipede (Chilopoda), Scorpion (Scorpionida) and Snake (Serpentes) Venoms", pages 33-39. * |
Also Published As
Publication number | Publication date |
---|---|
AU7518396A (en) | 1998-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5741669A (en) | Insecticidally effective peptides | |
US5695959A (en) | Recombinant expression of insecticidally effective spider toxin | |
US5688764A (en) | Insecticidal peptides from spider venom | |
US5461032A (en) | Insecticidally effective peptides | |
AU661997B2 (en) | Insecticidally effective peptides | |
US5756459A (en) | Insecticidally effective peptides isolatable from phidippus spider venom | |
CA2213444A1 (fr) | Toxines insecticides provenant de bracon hebetor | |
WO1996025429A9 (fr) | Toxines insecticides provenant de bracon hebetor | |
KR100274730B1 (ko) | 기생 말벌 브래콘 헤베터에서 유래한 살충성 독소 | |
WO1998017107A1 (fr) | Peptides a activite insecticide isoles a partir du venin de l'araignee phidippus | |
WO1998009522A1 (fr) | Fabrication de peptides insecticides a partir du venin d'araignee segestria sp. | |
WO1992011363A1 (fr) | Molecules recombinantes utiles pour produire des microbes insecticides | |
SI9210212A (sl) | Insekticidno učinkoviti peptid |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 1998519304 Format of ref document f/p: F |
|
122 | Ep: pct application non-entry in european phase |